Randomized, double blind and double dummy design. Primary efficacy endpoint based on a non-inferiority comparison of 'responders' following six months of treatment with either a dose of four Probuphine implants or treatment with 8 mg or less of an approved daily dosed sublingual tablet formulation of buprenorphine. Patient enrollment completed in November 2014 – two months ahead of schedule.
{}